Key features and details
- Expression system: Escherichia coli
- Purity: > 95% SDS-PAGE
- Tags: GST tag C-Terminus
- Suitable for: SDS-PAGE, ELISA, WB
Product nameRecombinant Human coronavirus SARS spike glycoprotein (Tagged)
See all SARS spike glycoprotein proteins and peptides
Purity> 95 % SDS-PAGE.
GS-4B Sepharose-Affinity Purification.
Expression systemEscherichia coli
Protein lengthProtein fragment
Predicted molecular weight38 kDa including tags
TagsGST tag C-Terminus
Additional sequence informationDerived from CUHK-L2. Mosaic protein – amino acids 408-470/540-573. Contains a mosaic of the immunodominant regions of the middle region of the Spike protein. Not full length spike protein.
Our Abpromise guarantee covers the use of ab270838 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Contains GST fusion partner. Immunoreactive with SARS positive sera.
Abcam has not and does not intend to apply for the REACH Authorisation of customers’ uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
Constituents: 0.4% Tris HCl, 0.4% Sarkosyl, 0.25% Triton-X-100, 50% Glycerol (glycerin, glycerine)
- E2 glycoprotein
- Human coronavirus spike glycoprotein
RelevanceA novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive stranded RNA approximately 27 to 31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab270838 has not yet been referenced specifically in any publications.